Arexvy powder and suspension for suspension for injection Respiratory Syncytial Virus (RSV) vaccine (recombinant clinical trials
6 indexed studies · 0 currently recruiting
- Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 3b, open-label study to evaluate the non-inferiority of the immune response and to evaluate the safety of the RSVPreF3 OA investigational vaccine in adults 18-49 years of age at increased risk of respiratory syncytial virus disease, compared to older adults ≥60 years of age.
This study is testing a new vaccine for RSV infection in adults aged 18-49 who are at higher risk. It compares how well their immune system responds to the vaccine to how older adults (60+) respond, and checks for any side effects.
For: Respiratory Syncytial Virus InfectionsGermany - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 3, open-label, randomized, controlled study to evaluate the immune response, safety and reactogenicity of RSVPreF3 OA investigational vaccine when co-administered with a COVID-19 mRNA vaccine (Omicron XBB.1.5) in adults aged 50 years and above.
This study is looking at a new vaccine for RSV (a common cold-like virus) in people aged 50 and over. It's testing if it works well and is safe when given at the same time as an updated COVID-19 vaccine.
For: Respiratory Syncytial Virus InfectionsSpain · Belgium · Netherlands - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase 2b, randomized, controlled, open-label study to evaluate the immune response and safety of the RSVPreF3 OA investigational vaccine in adults (≥18 years of age) when administered to lung and renal transplant recipients comparing 1 versus 2 doses and compared to healthy controls (≥50 years of age) receiving 1 dose
This study is looking at a new vaccine to protect people who have had lung or kidney transplants from a common bug called RSV. We want to see how well the vaccine works and if it's safe, by giving one or two doses and comparing it to healthy people.
For: Respiratory Syncytial Virus InfectionsSpain · Italy · Germany - Ongoing, recruitingPhase III and phase IV (Integrated)
A Phase 3, randomized, controlled, partially blind, immuno-bridging study to evaluate immunogenicity, reactogenicity, safety and the occurrence of RSV-associated respiratory tract illness after administration of a single dose of GSK’s RSVPreF3 OA investigational vaccine in adults aged 60 years and older.
This study is testing a new vaccine for older adults against a common chest infection called RSV. It looks at how well the vaccine works, if it causes side effects, and how safe it is for people aged 60 and over.
For: Respiratory Syncytial Virus InfectionsFinland · Poland · Spain - AuthorisedTherapeutic use (Phase IV)
Vaccination against respiratory syncytial virus in patients with inflammatory rheumatic diseases. The impact of anti-rheumatic treatments on the RSV immune response.
This study looks at how well RSV vaccines work in people with inflammatory rheumatic diseases. We want to see if their anti-rheumatic medicines affect how their body responds to the vaccine and creates protection against the RSV virus.
For: Inflammatory rheumatic diseaseSweden - AuthorisedTherapeutic use (Phase IV)
COPD-2VAX: Enhancing Protection Against Respiratory Infections Through AS01-Mediated Innate Immune Activation in High-Risk Patients
This study looks at how new vaccines for lung conditions and common infections work in people with COPD. It aims to see if these vaccines can help their body's defenses (immune system) fight off respiratory illnesses better.
For: Chronic Obstructive Pulmonary Disease (COPD)Denmark